Literature DB >> 27837307

Outcomes of Radiofrequency Perforation for Pulmonary Atresia and Intact Ventricular Septum: A Single-Centre Experience.

Steven Rathgeber1, Benjamin Auld1, Stephanie Duncombe1, Martin C K Hosking1, Kevin C Harris2.   

Abstract

Percutaneous radiofrequency perforation (RFP) of the pulmonary valve is used as a primary therapy in neonates with pulmonary atresia and intact ventricular septum (PAIVS). We sought to determine the safety and efficacy of RFP for PAIVS in a single center and assess the pre-intervention anatomical parameters associated with a biventricular outcome. We retrospectively reviewed all cases of PAIVS treated with RFP at a single center from 1999 through 2012. We collected baseline imaging data, technical aspects of the procedure, adverse events and outcomes. RFP was attempted in 18 patients with 17 successful procedures. There was no mortality; one patient had an acute complication requiring surgical intervention. All were alive at the most recent follow-up (median 4.9 years; IQR = 2.0-6.8 years), 12/17 (71%) had a biventricular circulation, 2/17 (12%) had a 1½ ventricle repair, 2/17 (12%) had a univentricular repair and 1/17 was lost to follow-up. A biventricular outcome in patients with PAIVS was associated with the pre-intervention tricuspid valve/mitral valve (TV/MV) ratio and tricuspid valve (TV) z-score. The median TV/MV ratio for patients who underwent a biventricular repair and a non-biventricular repair was 0.82 (IQR = 0.71-0.90) and 0.59 (IQR = 0.39-0.76), P = 0.036, respectively. The median TV z-scores were -3.2 [(-4.9 to -2.6), and -6.8 (-9.7 to -4.8] P = 0.036 for the biventricular and non-biventricular groups, respectively. RFP is a safe primary therapy for PAIVS. With appropriate patient selection, RFP will often result in a biventricular circulation. Both the TV/MV and TV z-score were found to be a predictor of a biventricular outcome in our cohort.

Entities:  

Keywords:  Cardiac catheterization; Pulmonary atresia; Valvotomy

Mesh:

Year:  2016        PMID: 27837307     DOI: 10.1007/s00246-016-1498-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  16 in total

1.  Usefulness of the preoperative tricuspid/mitral valve ratio for predicting outcome in pulmonary atresia with intact ventricular septum.

Authors:  L L Minich; L Y Tani; S Ritter; R V Williams; R E Shaddy; J A Hawkins
Journal:  Am J Cardiol       Date:  2000-06-01       Impact factor: 2.778

2.  Concomitant stenting of the patent ductus arteriosus and radiofrequency valvotomy in pulmonary atresia with intact ventricular septum and intermediate right ventricle: early in-hospital and medium-term outcomes.

Authors:  Mazeni Alwi; Kok-Kuan Choo; Nomee A M Radzi; Hasri Samion; Kiew-Kong Pau; Chee-Chin Hew
Journal:  J Thorac Cardiovasc Surg       Date:  2011-01-11       Impact factor: 5.209

3.  Perforation of the atretic pulmonary valve. Long-term follow-up.

Authors:  Gabriella Agnoletti; Jean François Piechaud; Philipp Bonhoeffer; Yacine Aggoun; Tony Abdel-Massih; Younes Boudjemline; Christine Le Bihan; Damien Bonnet; Daniel Sidi
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

4.  Pulmonary atresia with intact ventricular septum percutaneous radiofrequency-assisted valvotomy and balloon dilation versus surgical valvotomy and Blalock Taussig shunt.

Authors:  M Alwi; K Geetha; A A Bilkis; M K Lim; S Hasri; A L Haifa; A Sallehudin; R Zambahari
Journal:  J Am Coll Cardiol       Date:  2000-02       Impact factor: 24.094

5.  Relationship of the dimension of cardiac structures to body size: an echocardiographic study in normal infants and children.

Authors:  P E Daubeney; E H Blackstone; R G Weintraub; Z Slavik; J Scanlon; S A Webber
Journal:  Cardiol Young       Date:  1999-07       Impact factor: 1.093

6.  Outcomes of transcatheter approach for initial treatment of pulmonary atresia with intact ventricular septum.

Authors:  Babar Sultan Hasan; Victor Bautista-Hernandez; Doff B McElhinney; Joshua Salvin; Peter C Laussen; Ashwin Prakash; Robert L Geggel; Frank A Pigula
Journal:  Catheter Cardiovasc Interv       Date:  2012-10-17       Impact factor: 2.692

7.  Percutaneous balloon valvotomy in pulmonary atresia with intact ventricular septum: impact on patient care.

Authors:  Tilman Humpl; Björn Söderberg; Brian W McCrindle; David G Nykanen; Robert M Freedom; William G Williams; Lee N Benson
Journal:  Circulation       Date:  2003-07-28       Impact factor: 29.690

8.  Long-term functional health status and exercise test variables for patients with pulmonary atresia with intact ventricular septum: a Congenital Heart Surgeons Society study.

Authors:  Tara Karamlou; Jeffrey A Poynter; Henry L Walters; Jonathan Rhodes; Igor Bondarenko; Sara K Pasquali; Stephanie M Fuller; Linda M Lambert; Eugene H Blackstone; Marshall L Jacobs; Kim Duncan; Christopher A Caldarone; William G Williams; Brian W McCrindle
Journal:  J Thorac Cardiovasc Surg       Date:  2013-01-29       Impact factor: 5.209

9.  Long-term results of catheter-based treatment of pulmonary atresia and intact ventricular septum.

Authors:  M Marasini; P F Gorrieri; G Tuo; L Zannini; P Guido; M Pellegrini; S Bondanza; M G Calevo; G Pongiglione
Journal:  Heart       Date:  2009-05-28       Impact factor: 5.994

10.  Congenital heart disease: prevalence at livebirth. The Baltimore-Washington Infant Study.

Authors:  C Ferencz; J D Rubin; R J McCarter; J I Brenner; C A Neill; L W Perry; S I Hepner; J W Downing
Journal:  Am J Epidemiol       Date:  1985-01       Impact factor: 4.897

View more
  2 in total

1.  Optimal management of pulmonary atresia with intact ventricular septum in a developing country: the art of pulmonary valve mechanical perforation in the era of CTO hardware.

Authors:  Raymond N Haddad; Zakhia Saliba
Journal:  Am J Cardiovasc Dis       Date:  2021-02-15

2.  Type I and II pulmonary atresia with intact ventricular septum in infants: a 10-year experience in initial surgery at one center.

Authors:  Hailong Song; Ziying Chen
Journal:  BMC Cardiovasc Disord       Date:  2022-03-17       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.